At the time of writing, AnaptysBio Inc [ANAB] stock is trading at $18.95, up 1.61%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The ANAB shares have gain 10.95% over the last week, with a monthly amount glided 15.55%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
AnaptysBio Inc [NASDAQ: ANAB] stock has seen the most recent analyst activity on February 04, 2025, when Wolfe Research initiated its Outperform rating and assigned the stock a price target of $25. Previously, H.C. Wainwright downgraded its rating to Neutral on December 11, 2024, and dropped its price target to $19. On December 02, 2024, downgrade downgraded it’s rating to Neutral. H.C. Wainwright started tracking the stock assigning a Buy rating and suggested a price target of $55 on July 22, 2024. JP Morgan upgraded its rating to a Overweight and raised its price target to $69 on July 19, 2024. Leerink Partners started tracking with a Outperform rating for this stock on April 16, 2024, and assigned it a price target of $47. In a note dated April 11, 2024, Wells Fargo initiated an Overweight rating and provided a target price of $56 on this stock.
For the past year, the stock price of AnaptysBio Inc fluctuated between $12.21 and $41.31. Currently, Wall Street analysts expect the stock to reach $42.67 within the next 12 months. AnaptysBio Inc [NASDAQ: ANAB] shares were valued at $18.95 at the most recent close of the market. An investor can expect a potential return of 125.17% based on the average ANAB price forecast.
Analyzing the ANAB fundamentals
According to AnaptysBio Inc [NASDAQ:ANAB], the company’s sales were 91.28M for trailing twelve months, which represents an 378.77% jump. Gross Profit Margin for this corporation currently stands at 0.98% with Operating Profit Margin at -1.26%, Pretax Profit Margin comes in at -1.59%, and Net Profit Margin reading is -1.59%. To continue investigating profitability, this company’s Return on Assets is posted at -0.3, Equity is -2.73 and Total Capital is -0.26. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.23.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 18.51 points at the first support level, and at 18.06 for the second support level. However, for the 1st resistance point, the stock is sitting at 19.50, and for the 2nd resistance point, it is at 20.05.
Ratios To Look Out For
It is important to note that AnaptysBio Inc [NASDAQ:ANAB] has a current ratio of 9.51. As well, the Quick Ratio is 9.51, while the Cash Ratio is 2.71. Considering the valuation of this stock, the price to sales ratio is 6.37, the price to book ratio is 8.15.
Transactions by insiders
Recent insider trading involved EcoR1 Capital, LLC, Director, that happened on Dec 30 ’24 when 65184.0 shares were purchased. Director, EcoR1 Capital, LLC completed a deal on Dec 31 ’24 to buy 13268.0 shares. Meanwhile, Director EcoR1 Capital, LLC bought 6646.0 shares on Jan 02 ’25.
